Results 241 to 250 of about 146,196 (353)

Force generation of cardiomyocytes in engineered environments [PDF]

M. S. Sinha, Ulrike Rölleke, Ruben Haag, Malte Tiburcy, Johannes W. Blumberg, Ulrich S. Schwarz, Wolfram‐Hubertus Zimmermann, Sarah Köster   +7 more
openalex   +1 more source

Correction: Multi-sized microelectrode array coupled with micro-electroporation for effective recording of intracellular action potential. [PDF]

Microsyst Nanoeng
Xu X, Liu Z, Liu J, Yao C, Chen X, Huang X, Huang S, Shi P, Li M, Wang L, Tao Y, Chen HJ, Xie X.   +12 more
europepmc   +1 more source

LncRNA Lockd promotes cardiomyocyte proliferation via Eno1/beta-catenin/Myc axis

Shakti Prakash, S. Kundu, Ayushi Devendrasingh Chaudhary, Sakshi Chaudhary, Chandan Kumar, Sunaina Kumari, Sandhya Singh, Babita Yadav, Anuj Kumar, V.M. Prajapati, Kumaravelu Jagavelu, Shailesh Kumar, Shashi Kumar Gupta   +12 more
openalex   +1 more source

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li, Max Homilius, Erin Achilles, Laura K. Massey, Victoria Convey, Åsa Ohlsson, Ingrid Ljungvall, Jens Häggström, Brittany Vester Boler, Pascal Steiner, Sharlene Day, Calum A. MacRae, Mark A. Oyama   +12 more
wiley   +1 more source

Cardiomyocyte-Specific Smad7 Protects the Pressure-Overloaded Heart, Inhibiting the Transforming Growth Factor-β Receptor 1/Smad2/3 Cascade. [PDF]

J Am Heart Assoc
Humeres C, Tuleta I, Qin D, Shinde AV, Deepak A, Hanna A, Frangogiannis NG.   +6 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

White Wine Intake Reduces Mitochondrial Complex I-Derived ROS in the Male Rat Heart. [PDF]

Antioxidants (Basel)
Matijevic J, Grahovac M, Mornar M, Novak I, Ljubkovic M, Boban M, Marinovic J.   +6 more
europepmc   +1 more source

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats

ESC Heart Failure, Volume 12, Issue 2, Page 1304-1315, April 2025.
Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction
Einar Sjaastad Nordén, Bård Andre Bendiksen, Kaja Knudsen Bergo, Emil Knut Stenersen Espe, Gary McGinley, Almira Hasic, Ida Marie Hauge‐Iversen, Hege Katrin Ugland, Xin Shen, Michael Frisk, Nishani S. Mabotuwana, William E. Louch, Rizwan I. Hussain, Lili Zhang, Ivar Sjaastad, Alessandro Cataliotti, Geir Christensen   +16 more
wiley   +1 more source

Mesenchymal Stem Cell-Derived Exosomes: A Tool for Heart Failure Repair - From Molecular Mechanisms to Clinical Potential. [PDF]

J Inflamm Res
Chen MT, Wan ZX, Li YY, Li XL, Luo Y, Yang SY, Jiang H, Liu QY, Lyu R, Jiang Y, Luo G, Liu MN.   +11 more
europepmc   +1 more source